This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • NGR012 A phase II study of NGR-hTNF administered i...
Clinical trial

NGR012 A phase II study of NGR-hTNF administered in combination with doxorubicin every 3 weeks in patients affected by advanced or metastatic ovarian cancer

Read time: 1 mins
Last updated:10th Apr 2007
Antitumor activity defined as response rate according to RECIST criteria
Category Value
Study start date 2007-04-10

View full details